Dorel Juvenile reports strong performanceDorel Home taking further steps to return to profitability MONTRÉAL, May 12, 2025 (GLOBE NEWSWIRE) --…
ALMATY, Kazakhstan, May 12, 2025 (GLOBE NEWSWIRE) -- Joint Stock Company Kaspi.kz (“Kaspi.kz”, “we”) (Nasdaq:KSPI) which operates the Kaspi.kz and…
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market…
The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its…
First Quarter 2025 Highlights Revenue increased 17% to €311 millionProfit for the period increased to €24 million and expanded to…
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data…
Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment…
Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1…
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution…
HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for…
This website uses cookies.